July 27, 2021 5:52pm

However, the 3 p.m. hour saw a few buyers coming-in for scarce bottom fishing

Pre-open indications: 3 HITs and 2 MISS

My comments try to distinguish the temporary from real pricing digression or progress.

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers! 

The Dow closed DOWN -85.79 points (-0.24%); the S&P closed DOWN -20.84 points (-0.47%) while the Nasdaq closed DOWN -180.14 points (-1.21%)

 

Henry’omics:

The sector and market sell-off followed yet another session of heavy losses on Tuesday, ending a five-day winning streak in the three major indexes, as investors were cautious before results from top tech and internet names and Wednesday's Federal Reserve announcement.

The Nasdaq led the day's declines, registering its biggest daily percentage drop since May 12, but the three indexes pared losses heading into the close and ended well off the lows of the session.

Adding to the cautious tone is the outlook for U.S.-listed Chinese stocks – so, remember Biostage (BSTG).

 

Data Docket: The Federal Open Market Committee will release a statement when the meeting concludes Wednesday, followed by Chairman Jerome Powell’s news conference.

 

RegMed Investors’ (RMi) pre-open: slippage, drippage or both. Weak trading and minor percentage moves have defined the sector recently” … https://www.regmedinvestors.com/articles/12020

 

Q2/21 Earnings and dates of releases … https://www.regmedinvestors.com/articles/11542

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Tuesday opened negative at 2/31, 1 flat and 1 acquired, stayed negative at the mid-day to 6/26, 2 flats and 1 acquired, closing negative 7/25, 2 flats and 1 acquired;
  • Monday opened negative at 11/21, 2 flats and 1 acquired, stayed negative at the mid-day to 9/21, 4 flats and 1 acquired, closing negative 12/21, 1 flat and 1 acquired;

 

The Biostage (BSTG) Chronicles: Tuesday closed down -$0.00 with 43 shares traded after Monday’s downside of -$0.06 to $1.65 with 406 shares traded after Friday and Thursday closing flat with 200 shares traded, Wednesday closed +$0.01 to $1.71 with 200 shares traded, Tuesday’s volume of 49 shares with a flat outcome proves I am RIGHT re the “pump” promoting, following last Monday’s 207 shares traded dropping -$0.01 to $1.70.

  • WHY the “push/promote”; it is to exercise warrants adding more unregistered shares to the “outstanding” which is BSTG’s ONLY vehicle to raise money for operation continuation – they’re BROKE – so the only runway access is WHAT?

 

Pre-open Indications: 3 HITs <SELL: Biostage (BSTG -$0.00), uniQure NV (QURE -$1.22), Cellectis SA (CLLS -$0.18), bluebird bio (BLUE -$0.26)> 2 MISS < Ionis Pharmaceuticals (IONS -$.05), CRISPR Therapeutics (CRSP -$1.79)>  

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Vericel (VCEL), uniQure NV (QURE), BioLife Solutions (BLFS), Chinook Therapeutics (KDNY), Bellicum Pharmaceuticals (BLCM), Brainstorm Cell Therapeutics (BCLI), Athersys (ATHX) to name 7 of the 7 inclining of the 35

Hammered in today’s market:

  • Fate Therapeutics (FATE) - again, CRISPR Therapeutics (CRSP) – yet another again, Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY) - again, Ionis Pharmaceuticals (IONS) – again, to name 5 of the 25 declining of the 35 covered

 

Key Metrics:

  • Sector volume was LOW with 1 of the 7-upside having higher than the 3-month average volume with very LOW volume of 1 of 25-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 7-upside were +0.66% (ATHX) to +4.52% (QURE) while the 25-downside ranges from -0.09% (RARE) to -4.53% (ADVM);

 

Tuesday’s (7 of 7) incliners:

  • Vericel (VCEL +$1.67 after Monday’s -$1.66);
  • uniQure NV (QURE +$1.22 after Monday’s +$1.00);
  • BioLife Solutions (BLFS +$0.38 after Monday’s -$1.43);
  • Chinook therapeutics (KDNY +$0.23);
  • Bellicum Pharmaceuticals (BLCM +$0.06);
  • Brainstorm Cell Therapeutics (BLCM +$0.03);
  • Athersys (ATHX +$0.01 after Monday’s +$0.01);

Tuesday’s (10 of 25) decliners:

  • Fate Therapeutics (FATE -$2.87 after Monday’s -$3.18);
  • CRISPR Therapeutics (CRSP +$1.79 after Monday’s -$3.05);
  • Intellia Therapeutics (NTLA -$1.63 after Monday’s -$3.71);
  • Alnylam Pharmaceuticals (ALNY -$1.52 after Monday’s -$4.30);
  • Ionis Pharmaceuticals (IONS -$1.05);
  • Sage Therapeutics (SAGE -$1.01 after Monday’s -$0.69);
  • Regenxbio (RGNX -$0.76 after Monday’s -$1.64);
  • Editas Medicine (EDIT -$0.58 after Monday’s -$0.99);
  • Global Blood Therapeutics (GBT -$0.48);
  • bluebird bio (BLUE -$0.26 after Monday’s +$0.20);

Closing – 2 flats – ReNeuron (RENE.L), Biostage (BSTG) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -0.81% and XBI closed down -1%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +1.78 points or +10.13% at 19.36

Upside volume:

  • Tuesday: 1 out of the 7-upside had higher than the 3-month average volume;

Downside volume:

  • Tuesday: 1 out of the 25-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Tuesday’s percentage (%) of the 7-upside were +0.66% (ATHX) to +4.52% (QURE) while the 25-downside ranges from -0.09% (RARE) to -4.53% (ADVM);

 

July, first month of Q3/21:

Tuesday closed negative with 7 advancers, 25 decliners, 2 flats and 1 acquired

Monday (7/26) closed negative with 12 advancers, 21 decliners,1 flat and 1 acquired

 

The BOTTOM LINE: Sector volatility showed its full force today, it is beyond worries about new virus strains and  light summer trading as sentiment resides in the “outhouse”.

As I have stated throughout the month of July, “Sector share pricing has been subjected to a negative headwind”.

Adding some warning signs for investors – Q2 earnings on the horizon; although uniQure NV (QURE) scored home run with a solid net income and runway earnings debut.

A tool that hasn’t resonated … guidance is one factor of the sector. NO news has bake- in the decline of the sector.

Keep an eye on “runways” … as quarterly earnings come out

We have seen the first release of earnings; but, will the remainder of Q2 earnings “suck pond water”!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.